<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03087864</url>
  </required_header>
  <id_info>
    <org_study_id>2016_325</org_study_id>
    <nct_id>NCT03087864</nct_id>
  </id_info>
  <brief_title>PDL-1 Targeting in Resectable Oesophageal Cancer</brief_title>
  <acronym>PERFECT</acronym>
  <official_title>PDL-1 Targeting in Resectable Oesophageal Cancer: a Phase II Feasibility Study of Atezolizumab and Chemoradiation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives The primary objective of this study is to assess the feasibility of preoperative&#xD;
      treatment with atezolizumab combined with preoperative chemoradiation (carboplatin,&#xD;
      paclitaxel and radiation) in terms of completion of treatment with atezolizumab.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives The primary objective of the study of this study is to assess the feasibility of&#xD;
      preoperative treatment with atezolizumab combined with preoperative chemoradiation&#xD;
      (carboplatin, paclitaxel and radiation) in terms of completion of treatment with&#xD;
      atezolizumab.&#xD;
&#xD;
      Secondary objectives are:&#xD;
&#xD;
        -  To assess toxicities of atezolizumab alone and in combination with chemoradiation.&#xD;
&#xD;
        -  To assess completion of chemotherapy and radiation treatment&#xD;
&#xD;
        -  To assess withdrawal rate from surgery&#xD;
&#xD;
        -  To assess post-operative complications.&#xD;
&#xD;
        -  To assess pathological response.&#xD;
&#xD;
        -  To assess R0 resection rate.&#xD;
&#xD;
        -  To assess the relation between gut microbiota composition and response.&#xD;
&#xD;
        -  To assess the relation between gut microbiota composition and toxicity.&#xD;
&#xD;
      Explorative objectives are:&#xD;
&#xD;
      To perform exploratory biomarker analyses from tumor tissue and blood-derived samples and&#xD;
      correlate with safety and clinical outcome. Biomarker analyses include (but are not limited&#xD;
      to):&#xD;
&#xD;
        -  Expression of PD-1, PD-L1 and FOXP3, presence of tumor infiltrating CD8+/CD4+&#xD;
           cytotoxic/helper T lymphocytes, IFNγ expression, presence of tumor macrophages, STAT3&#xD;
           and STAT6 expression, MHC classI, MHC class II, EBV and MSI status on tumor tissue.&#xD;
&#xD;
        -  RNA sequencing and whole exome sequencing to develop a predictive profile for response&#xD;
           to treatment.&#xD;
&#xD;
        -  Analysis of ctDNA extracted from plasma of patients at four time points (baseline,&#xD;
           directly after chemoradiation, at surgery and 3 months after surgery) and analyzed using&#xD;
           Ion Torrent Next Generation sequence technology as a non-invasive marker for response to&#xD;
           treatment.&#xD;
&#xD;
        -  Analysis of peripheral blood mononuclear cells (PBMCs) extracted from whole blood of&#xD;
           patients at three time points ((baseline, directly after chemoradiation, at surgery) )&#xD;
&#xD;
        -  Duodenal biopsy and morning faeces sample analysis as predictor of response will be done&#xD;
           by HIT Chip flora mapping, an established sensitive RT-qPCR method which is developed&#xD;
           for exact and sensitive enumeration of bacterial population.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 28, 2017</start_date>
  <completion_date type="Actual">July 1, 2019</completion_date>
  <primary_completion_date type="Actual">July 1, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>feasibility defined as percentage completion of treatment with atezolizumab.</measure>
    <time_frame>up to 3 months</time_frame>
    <description>The primary endpoint is feasibility defined as percentage completion of treatment with atezolizumab</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of toxicity</measure>
    <time_frame>up to 3 months</time_frame>
    <description>Incidence and severity of toxicity defined to CTCAE v4.03 and Radiation Oncology Group (RTOG) criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage completion of chemotherapy and radiation treatment</measure>
    <time_frame>up to 3 months</time_frame>
    <description>Percentage completion of chemotherapy and radiation treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage withdrawal rate from surgery due to atezolizumab related complications</measure>
    <time_frame>up to 3 months</time_frame>
    <description>Percentage withdrawal rate from surgery due to atezolizumab related complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage delay of surgery due to atezolizumab related complications</measure>
    <time_frame>up to 3 months</time_frame>
    <description>Percentage delay of surgery due to atezolizumab related complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of post-operative complications to the Dindo classification</measure>
    <time_frame>up to 3 months</time_frame>
    <description>Incidence and severity of post-operative complications to the Dindo classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathological response according to the Mandard criteria</measure>
    <time_frame>up to 3 months</time_frame>
    <description>Pathological response according to the Mandard criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R0 resection rate.</measure>
    <time_frame>up to 3 months</time_frame>
    <description>R0 resection rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>up to 3 months</time_frame>
    <description>Progression free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>up to 3 months</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Potential biomarker development based on assessment of tumour biopsies, blood- and faecal samples and the proposed mechanism of action of study drugs.</measure>
    <time_frame>up to 3 months</time_frame>
    <description>Potential biomarker development based on assessment of tumour biopsies, blood- and faecal samples and the proposed mechanism of action of study drugs.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Esophageal Cancer, Stage II</condition>
  <condition>Esophageal Cancer Stage III</condition>
  <arm_group>
    <arm_group_label>Atezolizumab and Chemoradiation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atezolizumab 1200 mg i.v. day 1-22-43-64-85 Carboplatin AUC = 2 i.v day 1-8-15-22-29 Paclitaxel 50 mg/m2 i.v day 1-8-15-22-29 Radiotherapy 23 x 1.8 Gy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>Atezolizumab 1200 mg i.v. day 1-22-43-64-85</description>
    <arm_group_label>Atezolizumab and Chemoradiation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Chemotherapy</description>
    <arm_group_label>Atezolizumab and Chemoradiation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Chemotherapy</description>
    <arm_group_label>Atezolizumab and Chemoradiation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy 23 x 1.8 Gy</intervention_name>
    <description>Radiotherapy</description>
    <arm_group_label>Atezolizumab and Chemoradiation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically proven adenocarcinoma of the esophagus or gastro esophageal junction.&#xD;
&#xD;
          -  Surgical resectable (&lt;T4b, N0 or N+, M0), as determined by Endoscopic Ultra Sound&#xD;
             (EUS) and CT scan of neck, thorax and abdomen. Tumors that cannot be passed with an&#xD;
             endoscope for endoscopic ultrasound are eligible if all other criteria are fulfilled.&#xD;
&#xD;
          -  T1N+ tumors are eligible.&#xD;
&#xD;
          -  Tumor length longitudinal ≤ 10 cm; if larger than 10 cm, inclusion should be discussed&#xD;
             with the principal investigator.&#xD;
&#xD;
          -  If the tumor extends below the gastroesophageal (GE) junction into the proximal&#xD;
             stomach, the bulk of the tumor must involve the esophagus or GE junction.&#xD;
&#xD;
          -  Age ≥ 18.&#xD;
&#xD;
          -  ECOG performance status 0 or 1 (cf. Appendix A).&#xD;
&#xD;
          -  Adequate hematological, renal and hepatic functions defined as:&#xD;
&#xD;
               -  neutrophiles ≥ 1.5 x 109/L&#xD;
&#xD;
               -  platelets ≥ 100 x 109/L&#xD;
&#xD;
               -  hemoglobin ≥ 5.6 mmol&#xD;
&#xD;
               -  total bilirubin ≤ 1.5 x upper normal limit&#xD;
&#xD;
               -  creatinine clearance (Cockroft) &gt; 60 ml/min&#xD;
&#xD;
          -  Written, voluntary informed consent&#xD;
&#xD;
          -  Patients must be accessible to follow up and management in the treatment center&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Past or current history of malignancy other than entry diagnosis interfering with&#xD;
             prognosis of esophageal cancer.&#xD;
&#xD;
          -  Invasion of the tracheobronchial tree or presence of tracheoesophageal fistula.&#xD;
&#xD;
          -  T1N0 tumors or in situ carcinoma.&#xD;
&#xD;
          -  Pregnancy (positive serum pregnancy test), planning to become pregnant, and lactation.&#xD;
&#xD;
          -  Patient (male or female) is not willing to use highly effective methods of&#xD;
             contraception (per institutional standard) during treatment and for 6 months (male or&#xD;
             female) after the end of treatment.&#xD;
&#xD;
          -  Previous chemotherapy, radiotherapy, and/or treatment with checkpoint inhibitors.&#xD;
&#xD;
          -  Clinically significant cardiovascular disease (including myocardial infarction,&#xD;
             unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac&#xD;
             arrhythmia) precluding major surgery.&#xD;
&#xD;
          -  Pulmonary fibrosis and/or severely impaired lung function precluding major surgery.&#xD;
&#xD;
          -  Pre-existing motor or sensory neurotoxicity greater than WHO grade 1.&#xD;
&#xD;
          -  Serious underlying medical condition which would impair the ability of the patient to&#xD;
             receive the planned treatment, including prior allergic reactions to drugs containing&#xD;
             Cremophor, such as teniposide or cyclosporine.&#xD;
&#xD;
          -  Dementia or altered mental status that would prohibit the understanding and giving of&#xD;
             informed consent&#xD;
&#xD;
          -  Inadequate caloric- and/or fluid intake despite consultation of a dietician and/or&#xD;
             tube feeding.&#xD;
&#xD;
          -  Has an active autoimmune disease that has required systemic treatment in past 2 years&#xD;
             (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive&#xD;
             drugs). Replacement therapy (e.g., thyroxine for patients with a history of&#xD;
             autoimmune-related hypothyroidism, insulin for patients with type 1 diabetes mellitus,&#xD;
             or physiologic corticosteroid replacement therapy for adrenal or pituitary&#xD;
             insufficiency, etc.) is not considered a form of systemic treatment. Patients with&#xD;
             vitiligo with dermatological manifestations only are eligible to enter the study.&#xD;
&#xD;
          -  Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy (&gt;10&#xD;
             mg/day prednisone or equivalent) or any other form of immunosuppressive therapy within&#xD;
             7 days prior to the first dose of trial treatment.&#xD;
&#xD;
          -  Has evidence of interstitial lung disease or active, non-infectious pneumonitis.&#xD;
&#xD;
          -  Has an active infection requiring systemic therapy which has not resolved 3 days&#xD;
             (simple infection such as cystitis) to 7 days (severe infection such as&#xD;
             pyelonephritis) prior to the first dose of trial treatment.&#xD;
&#xD;
          -  Patients with prior allogeneic stem cell or solid organ transplantation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hanneke WM van Laarhoven, Prof. dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Academic Medical Center, Medical Oncology</name>
      <address>
        <city>Amsterdam</city>
        <zip>1100 DD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>March 14, 2017</study_first_submitted>
  <study_first_submitted_qc>March 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2017</study_first_posted>
  <last_update_submitted>May 8, 2020</last_update_submitted>
  <last_update_submitted_qc>May 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</investigator_affiliation>
    <investigator_full_name>H.W.M. van Laarhoven</investigator_full_name>
    <investigator_title>Prof. dr.</investigator_title>
  </responsible_party>
  <keyword>esophageal cancer</keyword>
  <keyword>PD-L1 inhibition</keyword>
  <keyword>chemoradiation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

